Clinical Impact of Change of FLT3 Mutation Status in Acute Myeloid Leukemia (AML) Patients

被引：0
|
作者：
Warren, M.
Luthra, R.
Yin, C. C.
Ravandi, F.
Medeiros, L. J.
Zuo, Z.
机构：
[1] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1588
引用
收藏
页码：379A / 379A
页数：1
相关论文
共 50 条
  • [21] The clinical development of FLT3 inhibitors in acute myeloid leukemia
    Knapper, Steven
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1377 - 1395
  • [22] Implementing RNAi Therapy Targeting FLT3 in Acute Myeloid Leukemia (AML)
    Ansari, Aysha
    Bahadur, Remant K. C.
    Nasrullah, Mohammad
    Sundaram, Daniel N. M.
    Burbano, Luis Morales
    Brandwein, Joseph
    Jiang, Xiaoyan
    Uludag, Hasan
    BLOOD, 2022, 140 : 7791 - 7792
  • [23] Clinical use of FLT3 inhibitors in acute myeloid leukemia
    Sutamtewagul, Grerk
    Vigil, Carlos E.
    ONCOTARGETS AND THERAPY, 2018, 11 : 7041 - 7052
  • [24] FLT3 inhibitors: clinical potential in acute myeloid leukemia
    Hospital, Marie-Anne
    Green, Alexa S.
    Maciel, Thiago T.
    Moura, Ivan C.
    Leung, Anskar Y.
    Bouscary, Didier
    Tamburini, Jerome
    ONCOTARGETS AND THERAPY, 2017, 10 : 607 - 615
  • [25] Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status.
    Singh, Harshabad
    Werner, Lillian
    DeAngelo, Daniel J.
    Amrein, Philip C.
    Wadleigh, Martha
    Ballen, Karen K.
    Fox, Edward
    Galinsky, Ilene
    Neuberg, Donna
    Stone, Richard M.
    Attar, Eyal C.
    BLOOD, 2010, 116 (21) : 1108 - 1108
  • [26] Evaluation of the impact of minimal residual disease on overall survival, and FLT3 mutation status in FLT3 mutation-positive patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the chrysalis phase 1/2 study
    Roellig, C.
    Levis, M.
    Perl, A.
    Altman, J.
    Cortes, J. E.
    Smith, C.
    Baer, M.
    Claxton, D.
    Jurcic, J.
    Ritchie, E.
    Strickland, S.
    Tibes, R.
    Hill, J.
    Liu, S.
    Bahceci, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 141 - 141
  • [27] NPM1 AND FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
    Aguiar, E.
    Amorim, M.
    Gomes, M. P.
    Guimaraes, P.
    Trigo, F.
    Guimaraes, J. E.
    HAEMATOLOGICA, 2012, 97 : 507 - 508
  • [28] FLT3 TYROSINE KINASE DOMAIN (TKD) MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Markova, J.
    Michkova, P.
    Maaloufova, J.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 550 - 550
  • [29] Incidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile
    Cabrera, Maria Elena
    Monardes, Virginia
    Salgado, Carmen
    Cares, Carolina
    Gonzalez, Claudio
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2023, 45 (01) : 77 - 82
  • [30] Safety of FLT3 inhibitors in patients with acute myeloid leukemia
    Cerchione, Claudio
    Peleteiro Raindo, Andres
    Mosquera Orgueira, Adrian
    Mosquera Torre, Alicia
    Bao Perez, Laura
    Marconi, Giovanni
    Isidori, Alessandro
    Perez Encinas, Manuel Mateo
    Martinelli, Giovanni
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 851 - 865
12345